Analyst Ratings for Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Viridian Therapeutics (NASDAQ:VRDN) received 13 bullish ratings from analysts, with no bearish or indifferent ratings. The company's average 12-month price target is $41.77, representing a 5.43% decrease from the previous average price target of $44.17.
September 13, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics received 13 bullish ratings from analysts in the last quarter, with an average 12-month price target of $41.77, a 5.43% decrease from the previous target.
The high number of bullish ratings indicates a positive sentiment towards Viridian Therapeutics among analysts. However, the decrease in the average price target could suggest a potential slowdown in the company's growth, which might impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100